Literature DB >> 26652771

Induction of Cytotoxicity in Pyridine Analogues of the Anti-metastatic Ru(III) Complex NAMI-A by Ferrocene Functionalization.

Changhua Mu, Stephanie W Chang, Kathleen E Prosser, Ada W Y Leung1, Stephanie Santacruz, Thalia Jang, John R Thompson, Donald T T Yapp1, Jeffrey J Warren, Marcel B Bally1, Timothy V Beischlag, Charles J Walsby.   

Abstract

A series of novel ferrocene (Fc) functionalized Ru(III) complexes was synthesized and characterized. These compounds are derivatives of the anti-metastatic Ru(III) complex imidazolium [trans-RuCl4(1H-imidazole) (DMSO-S)] (NAMI-A) and are derived from its pyridine analogue (NAMI-Pyr), with direct coupling of Fc to pyridine at the 4 or 3 positions, or at the 4 position via a two-carbon linker, which is either unsaturated (vinyl) or saturated (ethyl). Electron paramagnetic resonance (EPR) and UV-vis spectroscopic studies of the ligand exchange processes of the compounds in phosphate buffered saline (PBS) report similar solution behavior to NAMI-Pyr. However, the complex with Fc substitution at the 3 position of the coordinated pyridine shows greater solution stability, through resistance to the formation of oligomeric species. Further EPR studies of the complexes with human serum albumin (hsA) indicate that the Fc groups enhance noncoordinate interactions with the protein and help to inhibit the formation of protein-coordinated species, suggesting the potential for enhanced bioavailability. Cyclic voltammetry measurements demonstrate that the Fc groups modestly reduce the reduction potential of the Ru(III) center as compared to NAMI-Pyr, while the reduction potentials of the Fc moieties of the four compounds vary by 217 mV, with the longer linkers giving significantly lower values of E1/2. EPR spectra of the compounds with 2-carbon linkers show the formation of a high-spin Fe(III) species (S = 5/2) in PBS with a distinctive signal at g = 4.3, demonstrating oxidation of the Fe(II) ferrocene center and likely reflecting degradation products. Density functional theory calculations and paramagnetic (1)H NMR describe delocalization of spin density onto the ligands and indicate that the vinyl linker could be a potential pathway for electron transfer between the Ru and Fe centers. In the case of the ethyl linker, electron transfer is suggested to occur via an indirect mechanism enabled by the greater flexibility of the ligand. In vitro assays with the SW480 cell line reveal cytotoxicity induced by the ruthenium ferrocenylpyridine complexes that is at least an order of magnitude higher than the unfunctionalized complex, NAMI-Pyr. Furthermore, migration studies with LNCaP cells reveal that Fc functionalization does not reduce the ability of the compounds to inhibit cell motility. Overall, these studies demonstrate that NAMI-A-type compounds can be functionalized with redox-active ligands to produce both cytotoxic and anti-metastatic activity.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26652771     DOI: 10.1021/acs.inorgchem.5b02109

Source DB:  PubMed          Journal:  Inorg Chem        ISSN: 0020-1669            Impact factor:   5.165


  3 in total

1.  Ferrocene donor linked to pyridine/pyridinium acceptor via a systematically enlarged π-linker.

Authors:  Jiří Kulhánek; Milan Klikar; Oldřich Pytela; Zdenka Růžičková; Filip Bureš
Journal:  RSC Adv       Date:  2021-12-03       Impact factor: 4.036

2.  Transfer Hydrogenation and Antiproliferative Activity of Tethered Half-Sandwich Organoruthenium Catalysts.

Authors:  Feng Chen; Isolda Romero-Canelón; Joan J Soldevila-Barreda; Ji-Inn Song; James P C Coverdale; Guy J Clarkson; Jana Kasparkova; Abraha Habtemariam; Martin Wills; Viktor Brabec; Peter J Sadler
Journal:  Organometallics       Date:  2018-04-23       Impact factor: 3.876

Review 3.  Anticancer Ruthenium(III) Complexes and Ru(III)-Containing Nanoformulations: An Update on the Mechanism of Action and Biological Activity.

Authors:  Claudia Riccardi; Domenica Musumeci; Marco Trifuoggi; Carlo Irace; Luigi Paduano; Daniela Montesarchio
Journal:  Pharmaceuticals (Basel)       Date:  2019-09-26
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.